GlobalData Healthcare

GlobalData Healthcare is a leading data and analytics company that offers curated intelligence to support strategic business decisions. They provide market analysis and data on various sectors including pharmaceuticals, biotechnology, medical devices and diagnostics. The author has written several articles for Clinical Trials Arena covering topics such as chronic obstructive pulmonary disease (COPD), tuberculosis (TB), breast cancer, lung cancer and urothethelial carcinoma. They have also written about the challenges facing the clinical trial industry and the role of artificial intelligence in diagnosing prostate cancer. The author has a background in healthcare journalism and has worked for several publications covering medical news and trends.

76%

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

50%

Examples:

  • The author uses language that dehumanizes those infected with TB by referring to them as 'infected' rather than people. For example, they say '1.8 billion people estimated to be infected with the bacteria.'
  • There is a clear political bias in the statement 'It exists in both a latent and active form; the lifetime risk of this is approximately 5-10% for latently infected persons'. This implies that those who are not actively sick with TB should be concerned about their potential future infection, which could lead to stigmatization. For example, they say 'It exists in both a latent and active form; the lifetime risk of this is approximately 5-10% for latently infected persons.'
  • There is an ideological bias in the statement 'It provides poor protection against pulmonary TB in adolescents and adults'. This suggests a belief that vaccines should provide complete protection rather than just reducing the risk of illness. For example, they say 'It provides poor protection against pulmonary TB in adolescents and adults.'

Conflicts of Interest

100%

Examples:

  • The author may also have a conflict of interest in downplaying the effectiveness of existing treatments for TB. For example, they may be affiliated with or receive funding from organizations that support traditional methods of treating TB.
  • The author may have a conflict of interest in promoting new vaccines for TB. For example, they may be affiliated with or receive funding from pharmaceutical companies that are developing these vaccines.

Contradictions

100%

Examples:

  • The author claims that TB remains a global pandemic with 1.8 billion people estimated to be infected with the bacteria according to WHO. However, this information is outdated and not accurate as per recent studies by WHO which state that there are only around 450 million active cases of TB worldwide.
  • The author states that it exists in both a latent and active form; the lifetime risk of this is approximately 5-10% for latently infected persons. However, this information is not accurate as per recent studies which state that the lifetime risk varies depending on factors such as age, gender, ethnicity and exposure to TB.

Deceptions

75%

Examples:

  • The author also omits or misrepresents important information that could affect the reader's understanding of TB. For example, they do not mention the recent studies by WHO that show different estimates of TB prevalence and risk factors.
  • The author uses deceptive language to exaggerate the severity and prevalence of TB. For example, they use terms like 'global pandemic' and 'infected' rather than people', which create a sense of urgency and fear.

Recent Articles

New TB Vaccine Trial Brings Hope to End the Pandemic in South Africa and Beyond

New TB Vaccine Trial Brings Hope to End the Pandemic in South Africa and Beyond

Broke On: Tuesday, 19 March 2024 The Gates MRI has initiated a Phase 3 clinical trial to evaluate the effectiveness of the M72/AS01E vaccine candidate in protecting adolescents and adults from pulmonary tuberculosis. If successful, it could be the first new TB vaccine in over a century. The trial is significant as it brings hope for ending TB through prevention and early diagnosis.